RS53246B - Derivati imidazola kao inhibitori kazein kinaze - Google Patents

Derivati imidazola kao inhibitori kazein kinaze

Info

Publication number
RS53246B
RS53246B RS20140157A RSP20140157A RS53246B RS 53246 B RS53246 B RS 53246B RS 20140157 A RS20140157 A RS 20140157A RS P20140157 A RSP20140157 A RS P20140157A RS 53246 B RS53246 B RS 53246B
Authority
RS
Serbia
Prior art keywords
imidazol
fluorophenyl
pyrimidin
pharmaceutically acceptable
piperidin
Prior art date
Application number
RS20140157A
Other languages
English (en)
Serbian (sr)
Inventor
Chakrapani Subramanyam
Travis T. Wager
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of RS53246B publication Critical patent/RS53246B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20140157A 2009-10-28 2010-10-20 Derivati imidazola kao inhibitori kazein kinaze RS53246B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25550609P 2009-10-28 2009-10-28
PCT/IB2010/054749 WO2011051858A1 (en) 2009-10-28 2010-10-20 Imidazole derivatives as casein kinase inhibitors

Publications (1)

Publication Number Publication Date
RS53246B true RS53246B (sr) 2014-08-29

Family

ID=43301770

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20140157A RS53246B (sr) 2009-10-28 2010-10-20 Derivati imidazola kao inhibitori kazein kinaze

Country Status (22)

Country Link
US (1) US8518944B2 (enExample)
EP (1) EP2493876B1 (enExample)
JP (1) JP5784620B2 (enExample)
KR (1) KR101421852B1 (enExample)
CN (1) CN102686580B (enExample)
AR (1) AR078797A1 (enExample)
AU (1) AU2010311035B2 (enExample)
CA (1) CA2777632C (enExample)
DK (1) DK2493876T3 (enExample)
ES (1) ES2460065T3 (enExample)
HR (1) HRP20140252T1 (enExample)
IL (1) IL219190A0 (enExample)
IN (1) IN2012DN03182A (enExample)
MX (1) MX2012004997A (enExample)
PL (1) PL2493876T3 (enExample)
PT (1) PT2493876E (enExample)
RS (1) RS53246B (enExample)
SI (1) SI2493876T1 (enExample)
TW (1) TW201125864A (enExample)
UY (1) UY32977A (enExample)
WO (1) WO2011051858A1 (enExample)
ZA (1) ZA201202776B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
SI2654750T1 (sl) * 2010-12-20 2017-04-26 Pfizer Inc. Nove kondenzirane piridinske spojine kot inhibitorji kazein-kinaz
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
JP6267231B2 (ja) 2012-12-21 2018-01-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール
WO2014192868A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 環状アミノメチルピリミジン誘導体
WO2015119579A1 (en) 2014-02-07 2015-08-13 Agency For Science, Technology And Research 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US10722513B2 (en) 2015-03-23 2020-07-28 The University Of Melbourne Treatment of respiratory diseases
US11185536B2 (en) * 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
AU2017212655B2 (en) 2016-01-29 2024-01-18 Decibel Therapeutics, Inc. Expansion and differentiation of inner ear supporting cells and methods of use thereof
WO2018201192A1 (en) * 2017-05-03 2018-11-08 The University Of Melbourne Compounds for the treatment of respiratory diseases
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
CN113301900B (zh) * 2018-09-09 2024-11-29 夸纳特制药股份公司 酪蛋白激酶1抑制剂在治疗血管疾病中的应用
AU2019374731B2 (en) * 2018-11-07 2025-08-21 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
EP4126878A4 (en) * 2020-03-27 2024-07-10 Gritscience Biopharmaceuticals Co., Ltd. COMPOUNDS AS CASEIN KINASE INHIBITORS
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012154A1 (en) * 1990-12-31 1992-07-23 Fujisawa Pharmaceutical Co., Ltd. Imidazotriazine derivatives
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Cns損傷についての新規な治療
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
EP1404864A4 (en) * 2001-06-18 2008-05-28 Univ Rockefeller REGULATION OF NEURONAL FUNCTION OVER SIGNAL PATHS OF THE METABOTROPIC GLUTAMATE RECEPTOR
JP4691506B2 (ja) * 2003-12-11 2011-06-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド カゼインキナーゼIεの阻害剤としての置換1H−ピロロ[3,2−b,3,2−c,及び2,3−c]ピリジン−2−カルボキシアミド及び関連類似物
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
ES2334927T3 (es) * 2004-08-19 2010-03-17 Aventis Pharmaceuticals Inc. Derivados de 3-ariltioindol-2-carboxamida y sus analogos como imhibidores de caseina quinasa i.
ATE517874T1 (de) * 2005-10-21 2011-08-15 Exelixis Inc Pyrimidinone als modulatoren von caseinkinase ii (ck2)
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
SI2654750T1 (sl) 2010-12-20 2017-04-26 Pfizer Inc. Nove kondenzirane piridinske spojine kot inhibitorji kazein-kinaz

Also Published As

Publication number Publication date
CA2777632A1 (en) 2011-05-05
CN102686580B (zh) 2014-09-10
IN2012DN03182A (enExample) 2015-09-25
ZA201202776B (en) 2013-06-26
KR20120088759A (ko) 2012-08-08
DK2493876T3 (en) 2014-03-10
US20110098272A1 (en) 2011-04-28
CA2777632C (en) 2014-02-25
AR078797A1 (es) 2011-12-07
HK1171220A1 (en) 2013-03-22
EP2493876A1 (en) 2012-09-05
PL2493876T3 (pl) 2014-06-30
HRP20140252T1 (hr) 2014-04-25
MX2012004997A (es) 2012-06-12
WO2011051858A1 (en) 2011-05-05
TW201125864A (en) 2011-08-01
JP2013509392A (ja) 2013-03-14
PT2493876E (pt) 2014-03-20
JP5784620B2 (ja) 2015-09-24
AU2010311035A1 (en) 2012-05-03
CN102686580A (zh) 2012-09-19
SI2493876T1 (sl) 2014-04-30
EP2493876B1 (en) 2014-02-12
IL219190A0 (en) 2012-06-28
UY32977A (es) 2011-05-31
ES2460065T3 (es) 2014-05-13
AU2010311035B2 (en) 2013-05-16
US8518944B2 (en) 2013-08-27
KR101421852B1 (ko) 2014-07-22

Similar Documents

Publication Publication Date Title
JP5784620B2 (ja) カゼインキナーゼ阻害剤としてのイミダゾール誘導体
EP3181133B1 (en) Novel fused pyridine compounds as casein kinase inhibitors
JP4567099B2 (ja) ベンズイミダゾール誘導体
JP2016530259A (ja) ピリジノン
KR20110082189A (ko) 아밀로이드 베타의 조절제
EP2627650A2 (en) N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
JPWO2009051112A1 (ja) アミド化合物およびその用途
KR20110086769A (ko) 베타 세크레타제 억제제로서의 락탐
US20120202787A1 (en) Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators
HK1171220B (en) Imidazole derivatives as casein kinase inhibitors
WO2024254490A1 (en) Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase